Visão geral da empresa
A biotechnology firm operating within the broader healthcare sector, Seer, Inc. focuses on developing and commercializing specialized products designed to decode the complex biology of the proteome, aiming to improve human health outcomes across a diverse international footprint that includes the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers the Proteograph Product Suite, which serves as an integrated solution for its clients in these global markets. Seer, Inc. maintains a market capitalization of $95.35M and employs a workforce of 124 individuals to support its research and commercialization efforts. With annual revenue totaling $16.58M, the company's market cap and revenue figures indicate that it is a small-cap entity with a relatively modest revenue base compared to large-cap pharmaceutical peers. This scale suggests the company is in a growth-oriented phase where capital allocation is likely prioritized toward product development and market expansion rather than maximizing immediate profitability per share.
Saúde financeira
Seer, Inc. reported revenue of $16.58M over the trailing twelve months, yet generated a net income of -$73.6M and an EBITDA of -$71.888M. The substantial disparity between the positive revenue of $16.58M and the significant negative net income of -$73.6M reveals a cost structure where operating expenses and research and development costs far exceed the company's top-line earnings. The company's free cash flow stands at -$27.648M, indicating a heavy reliance on external capital sources to fund operations and strategic initiatives rather than generating internal cash reserves. Despite the negative free cash flow, the balance sheet retains $185.90M in cash against total debt of $23.65M, suggesting a conservative liquidity position with ample resources available to cover obligations. The debt-to-equity ratio of 9.12, while mathematically high, reflects a capital structure heavily weighted toward equity financing rather than debt obligations, given the minimal debt load relative to cash holdings. Furthermore, the current ratio of 12.84 demonstrates exceptional short-term liquidity, implying the company possesses more than twelve times the current assets needed to cover its current liabilities. Return on Equity is recorded at -25.1% and Return on Assets at -14.7%, metrics that reveal the company is currently diluting shareholder value and asset efficiency as it invests heavily in future growth before achieving sustainable profitability.
Avaliação de valorização
The valuation metrics for Seer, Inc. present a unique scenario where the P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is calculated at -1.61. The difference between these figures, specifically the negative forward P/E, implies that the market is pricing in the expectation that earnings will remain negative or require significant time to turn positive, rather than reflecting a standard earnings multiple. The Price to Book ratio stands at 0.37, which indicates that the stock is trading at a significant discount to its book value, suggesting the market may be undervaluing the company's assets or anticipating substantial future cost reductions. Alternative valuation metrics such as the Price to Sales ratio of 5.75 and an EV/EBITDA of 0.93 suggest the company is valued based on its revenue generation capabilities rather than current profitability, a common practice for early-stage biotechnology firms. The stock's price range over the last year fluctuated between a 52-Week High of $2.41 and a 52-Week Low of $1.65. Without a specific current share price provided in the facts to calculate a precise percentage, the range itself highlights the volatility inherent in small-cap biotech stocks, where prices can swing significantly based on clinical trial results or partnership announcements. The Beta of 1.60 indicates that the stock's price volatility is 60% higher than the broader market, meaning it experiences amplified price swings during periods of market turbulence.
Growth & Income
Seer, Inc. demonstrated a Revenue Growth (YoY) of 5.0%, while the Earnings Growth (YoY) is listed as N/A due to the absence of positive earnings history. Since earnings are negative, they cannot grow faster than revenue in the traditional sense; rather, the company is prioritizing revenue expansion through product adoption in its international markets, which implies a strategy focused on scaling top-line numbers before optimizing the bottom line. As the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, all generated cash and potential future earnings are reinvested directly into research, development, and commercialization efforts rather than being distributed to shareholders. This reinvestment approach is typical for biotechnology companies that require continuous funding to advance their proteome decoding technologies and maintain their competitive position in the global life sciences landscape. The overall growth and income profile is characterized by steady top-line expansion supported by a robust cash reserve, but with no current income generation for investors seeking dividend yields.